VEGF121 and VEGF165 Regulate Blood Vessel Diameter Through Vascular Endothelial Growth Factor Receptor 2 in an in vitro Angiogenesis Model

Vascular endothelial growth factor (VEGF) is essential for the induction of angiogenesis and drives both endothelial cell (EC) proliferation and migration. It has been suggested that VEGF also regulates vessel diameter, although this has not been tested explicitly. The two most abundant isoforms, VEGF121 and VEGF165, both signal through VEGF receptor 2 (VEGFR-2). We recently optimized a three-dimensional in vitro angiogenesis assay using HUVECs growing on Cytodex beads and embedded in fibrin gels. Fibroblasts provide critical factors that promote sprouting, lumen formation, and vessel stability. Using this assay, we have examined the role of VEGF in setting vessel diameter. Low concentrations of both VEGF121 and VEGF165 promote growth of long, thin vessels, whereas higher concentrations of VEGF remarkably enhance vessel diameter. Placental growth factor, which binds to VEGFR-1 but not VEGFR-2, does not promote capillary sprouting. Moreover, specific inhibition of VEGFR-2 signaling results in a dramatic reduction of EC sprouting in response to VEGF, indicating the critical importance of this receptor. The increase in vessel diameter is the result of cell proliferation and migration, rather than cellular hypertrophy, and likely depends on MEK1-ERK1/2 signaling. Both phosphatidylinositol 3-kinase and p38 activity are required for cell survival. We conclude that the diameter of new capillary sprouts can be determined by the local concentration of VEGF and that the action of VEGF on angiogenic EC in this assay is critically dependent on signaling through VEGFR-2.

[1]  J. Greenwood.  Astrocytes, Cerebral Endothelium, and Cell Culture , 1991, Annals of the New York Academy of Sciences.

[2]  Shawn M. Sweeney,et al.  Angiogenesis in Collagen I Requires α2β1 Ligation of a GFP*GER Sequence and Possibly p38 MAPK Activation and Focal Adhesion Disassembly* , 2003, Journal of Biological Chemistry.

[3]  W. Sessa,et al.  Akt Down-regulation of p38 Signaling Provides a Novel Mechanism of Vascular Endothelial Growth Factor-mediated Cytoprotection in Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[4]  R. Sainson,et al.  Angiogenic sprouting and capillary lumen formation modeled by human umbilical vein endothelial cells (HUVEC) in fibrin gels: the role of fibroblasts and Angiopoietin-1. , 2003, Microvascular research.

[5]  Detlev Drenckhahn,et al.  A microcarrier-based cocultivation system for the investigation of factors and cells involved in angiogenesis in three-dimensional fibrin matrices in vitro , 1995, Histochemistry and Cell Biology.

[6]  R K Jain,et al.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.

[7]  V Nehls,et al.  A novel, microcarrier-based in vitro assay for rapid and reliable quantification of three-dimensional cell migration and angiogenesis. , 1995, Microvascular research.

[8]  T. Yagi,et al.  A requirement for neuropilin-1 in embryonic vessel formation. , 1999, Development.

[9]  V. Nehls,et al.  The effect of fibroblasts, vascular smooth muscle cells, and pericytes on sprout formation of endothelial cells in a fibrin gel angiogenesis system. , 1994, Microvascular research.

[10]  P. Bernatchez,et al.  Regulation of VEGF‐induced endothelial cell PAF synthesis: role of p42/44 MAPK, p38 MAPK and PI3K pathways , 2001, British journal of pharmacology.

[11]  J. Folkman.  Tumor angiogenesis. , 1985, Advances in cancer research.

[12]  M. Shibuya,et al.  VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells , 1999, Oncogene.

[13]  Jiahuai Han,et al.  Requisite Role of p38 MAPK in Mural Cell Recruitment during Angiogenesis in the Rat Aorta Model , 2003, Journal of Vascular Research.

[14]  K. Pumiglia,et al.  Vascular Endothelial Growth Factor Induction of the Angiogenic Phenotype Requires Ras Activation* , 2001, The Journal of Biological Chemistry.

[15]  Jin Chen,et al.  The ephrins and Eph receptors in angiogenesis. , 2002, Cytokine & growth factor reviews.

[16]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[17]  P. Carmeliet,et al.  Molecular mechanisms of blood vessel growth. , 2001, Cardiovascular research.

[18]  Willem Flameng,et al.  Impaired myocardial angiogenesis and ischemic cardiomyopathy in mice lacking the vascular endothelial growth factor isoforms VEGF164 and VEGF188 , 1999, Nature Medicine.

[19]  Thomas N. Sato,et al.  Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. , 1997, Science.

[20]  P. Carmeliet.  Mechanisms of angiogenesis and arteriogenesis , 2000, Nature Medicine.

[21]  J. Winer,et al.  Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1/KDR. , 1994, The Journal of biological chemistry.

[22]  T. Kitsukawa,et al.  Targeting of both mouse neuropilin-1 and neuropilin-2 genes severely impairs developmental yolk sac and embryonic angiogenesis , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Persico.  Placenta Growth Factor , 2001 .

[24]  N. Ferrara,et al.  The biology of VEGF and its receptors , 2003, Nature Medicine.

[25]  S. Hubbard,et al.  Identification of substituted 3-[(4,5,6, 7-tetrahydro-1H-indol-2-yl)methylene]-1,3-dihydroindol-2-ones as growth factor receptor inhibitors for VEGF-R2 (Flk-1/KDR), FGF-R1, and PDGF-Rbeta tyrosine kinases. , 2000, Journal of medicinal chemistry.

[26]  H. Dvorak,et al.  Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. , 1995, The American journal of pathology.

[27]  J. Rossant,et al.  Role of the Flt-1 receptor tyrosine kinase in regulating the assembly of vascular endothelium , 1995, Nature.

[28]  S. Arkins,et al.  Requirement for phosphatidylinositol 3'-kinase to protect hemopoietic progenitors against apoptosis depends upon the extracellular survival factor. , 1996, Journal of immunology.

[29]  J. Fiddes,et al.  The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. , 1991, The Journal of biological chemistry.

[30]  J. Folkman,et al.  Tumor angiogenesis: a possible control point in tumor growth. , 1975, Annals of internal medicine.

[31]  W. Risau,et al.  Mechanisms of angiogenesis , 1997, Nature.

[32]  P. Ratcliffe,et al.  Regulation of angiogenesis by hypoxia: role of the HIF system , 2003, Nature Medicine.

[33]  R. Nicosia,et al.  Paracrine interactions between fibroblasts and endothelial cells in a serum-free coculture model. Modulation of angiogenesis and collagen gel contraction. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[34]  T. Gridley.  Notch Signaling in Vertebrate Development and Disease , 1997, Molecular and Cellular Neuroscience.

[35]  J. Huot,et al.  Integrin αvβ3 requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF , 2003, Cell stress & chaperones.

[36]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[37]  Pamela F. Jones,et al.  Requisite Role of Angiopoietin-1, a Ligand for the TIE2 Receptor, during Embryonic Angiogenesis , 1996, Cell.

[38]  F. Larcher,et al.  VEGF/VPF overexpression in skin of transgenic mice induces angiogenesis, vascular hyperpermeability and accelerated tumor development , 1998, Oncogene.

[39]  Stanley J. Wiegand,et al.  Vascular-specific growth factors and blood vessel formation , 2000, Nature.

[40]  K. Plate,et al.  Up-regulation of flk-1/vascular endothelial growth factor receptor 2 by its ligand in a cerebral slice culture system. , 1997, Cancer research.

[41]  Ingeborg Stalmans,et al.  Arteriolar and venular patterning in retinas of mice selectively expressing VEGF isoforms. , 2002, The Journal of clinical investigation.

[42]  J. Huot,et al.  Integrating the VEGF signals leading to actin-based motility in vascular endothelial cells. , 2000, Trends in cardiovascular medicine.

[43]  J. Peng,et al.  Increased hemangioblast commitment, not vascular disorganization, is the primary defect in flt-1 knock-out mice. , 1999, Development.

[44]  P. Krieg,et al.  VEGF mediates angioblast migration during development of the dorsal aorta in Xenopus. , 1998, Development.

[45]  David A. Cheresh,et al.  Get a ligand, get a life: integrins, signaling and cell survival , 2002, Journal of Cell Science.

[46]  F. Diella,et al.  Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis. , 1999, Genes & development.

[47]  D. Shima,et al.  The Mouse Gene for Vascular Endothelial Growth Factor , 1996, The Journal of Biological Chemistry.

[48]  G. Yancopoulos,et al.  Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells. , 2001, Developmental biology.

[49]  R. Friesel,et al.  Molecular mechanisms of angiogenesis: fibroblast growth factor signal transduction , 1995, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[50]  C. Drake,et al.  VEGF and Vascular Fusion: Implications for Normal and Pathological Vessels , 1999, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[51]  G. E. Gilbert,et al.  Slowed Release of Thrombin-cleaved Factor VIII from von Willebrand Factor by a Monoclonal and a Human Antibody Is a Novel Mechanism for Factor VIII Inhibition* , 1996, The Journal of Biological Chemistry.

[52]  K. Alitalo,et al.  Involvement of VEGFR-2 (kdr/flk-1) but not VEGFR-1 (flt-1) in VEGF-A and VEGF-C-induced tube formation by human microvascular endothelial cells in fibrin matrices in vitro , 2004, Angiogenesis.

[53]  J. Berman,et al.  Human fetal astrocytes induce the expression of blood-brain barrier specific proteins by autologous endothelial cells , 1993, Brain Research.

[54]  Taro Matsumoto,et al.  p38 MAP kinase negatively regulates endothelial cell survival, proliferation, and differentiation in FGF-2–stimulated angiogenesis , 2002, The Journal of cell biology.

[55]  G. Cooper,et al.  Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. , 1995, Science.

[56]  Shur-Jen Wang,et al.  The Basic Helix-Loop-Helix Transcription Factor HESR1 Regulates Endothelial Cell Tube Formation* , 2001, The Journal of Biological Chemistry.

[57]  Christopher C W Hughes,et al.  Notch activation during endothelial cell network formation in vitro targets the basic HLH transcription factor HESR-1 and downregulates VEGFR-2/KDR expression. , 2002, Microvascular research.

[58]  Harold E. Dvorak,et al.  Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels , 1991, The Journal of experimental medicine.

[59]  L Orci,et al.  Paracrine induction of angiogenesis in vitro by Swiss 3T3 fibroblasts. , 1993, Journal of cell science.

[60]  K. Shitara,et al.  Roles of two VEGF receptors, Flt-1 and KDR, in the signal transduction of VEGF effects in human vascular endothelial cells , 2000, Oncogene.

[61]  G. Yancopoulos,et al.  Growth factors acting via endothelial cell-specific receptor tyrosine kinases: VEGFs, angiopoietins, and ephrins in vascular development. , 1999, Genes & development.

[62]  Vishva Dixit,et al.  Vascular Endothelial Growth Factor Regulates Endothelial Cell Survival through the Phosphatidylinositol 3′-Kinase/Akt Signal Transduction Pathway , 1998, The Journal of Biological Chemistry.